Outcomes for COPD pharmacological trials: from lung function to biomarkers

M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, P. W. Jones, D. A. Mahler, B. Make, M. Miravitlles, C. P. Page, P. Palange, D. Parr, M. Pistolesi, S. I. Rennard, M. P. Rutten-Van MoelkenR. Stockley, S. D. Sullivan, J. A. Wedzicha, E. F. Wouters

Research output: Contribution to journalLiterature reviewpeer-review

Abstract

The American Thoracic Society/European Respiratory Society jointly created a Task Force on "Outcomes for COPD pharmacological trials: from lung function to biomarkers" to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers when evaluating the impact of a pharmacological therapy. Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations.

Original languageEnglish
Pages (from-to)416-468
Number of pages53
JournalEuropean Respiratory Journal
Volume31
Issue number2
DOIs
Publication statusPublished - Feb 2008

Cite this